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ABSTRACT
Disposition and urinary excretion of levofl oxacin following a single intravenous administration of 4 mg/kg 
body mass were investigated in six febrile crossbred calves. The drug levels in plasma and urine were estimated 
by microbiological assay. Levofl oxacin was rapidly distributed from the blood to the tissue compartment, as 
evidenced by the high values of the distribution coeffi cient (9.93 ± 0.73 h-1). The high AUC (11.5 ± 0.95 
g/mL/h) indicated good antibacterial activity of levofl oxacin in calves. The elimination half-life, volume of 
distribution and total body clearance were 2.22 ± 0.07 h, 1.18 ± 0.15 L/kg and 0.36 ± 0.03 L/kg/h, respectively. 
About 37.7 per cent of the administered dose of levofl oxacin was eliminated in urine within 24 h. An appropriate 
intravenous dosage regimen for levofl oxacin would be 5.0 mg/kg, repeated at 12 h intervals for the treatment of 
bacterial infections, manifested with fever in calves. 
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Introduction 
Fever is one of the most common manifestations of all bacterial infections and is 
known to induce several biochemical and physiological alterations in cells (VANMIERT, 
1987; LOHUIS et al., 1988). Febrile conditions have been reported to markedly alter the 
disposition of antibacterials in bovines (DUMKA et al., 2000; CHAUDHARY et al., 2002; 
DARDI et al., 2005). Levofl oxacin possesses excellent activity against gram-positive, 
gram-negative and anaerobic bacteria (DAVIS and BRYSON, 1994; NORTH et al., 1998) and 
has pronounced bactericidal activity against resistant organisms, such as Pseudomonas, 
Enterobacteriaceae and Klebsiella (KLESEL et al., 1995). Levofl oxacin has been found to 
be very effective in the treatment of infections of the upper and lower respiratory tract, 
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genitourinary system, skin and soft tissue (DAVIS and BRYSON, 1994). About 80% of the 
administered dose of levofl oxacin in man was found in urine as the unchanged drug and 
≤5% as inactive metabolites (LANGTRY and LAMB, 1998). The disposition of levofl oxacin 
has been investigated in man (CHULAVATNATOL et al., 1999), rabbits (DESTACHE et al., 
2001), calves (DUMKA and SRIVASTAVA, 2006; DUMKA and SRIVASTAVA, 2007), rats 
(ITO et al., 1999) and guinea pigs (EDELSTEIN et al., 1996). However, information on the 
disposition of levofl oxacin in cattle species under febrile conditions is completely lacking. 
In view of the paucity of pharmacokinetic data of levofl oxacin in febrile conditions in 
cattle, the present study was undertaken to determine the disposition, urinary excretion 
and an appropriate dosage regimen of levofl oxacin during E. coli endotoxin-induced 
fever, in cross bred calves following its single intravenous administration. 
Materials and methods 
Experimental animals and induction of fever. The experiments were performed on 6 
healthy male cross bred calves (Holstein Friesian x Sahiwal) of 1-1.5 years with an average 
body mass of 87.8 ± 13.1 kg. The animals were dewormed and kept under observation for 
two weeks of acclimatization before the commencement of the experiment. During the 
experimental period, the animals were maintained on concentrate and free grazing. Water 
was provided ad libitum. The experimental protocol followed the ethical guidelines on 
the proper care and use of animals. Fever was induced by a single intravenous injection 
of freshly prepared 1% E. coli endotoxin solution in sterilized normal saline, at a dose 
rate of 1 g/kg  body mass. E. coli endotoxin (lipopolysaccharide, serotype 055:B5) was 
purchased commercially from Sigma Chemicals Co., USA. The rise in body temperature 
was monitored by frequent recording of rectal temperature.
Drug administration. After induction of fever, levofl oxacin [Tavanic (0.5% 
Levofl oxacin), Hoechst Marion Roussel Ltd., India] was administered at a dose rate of 4 
mg/kg body mass into the left jugular vein. The dosage level of levofl oxacin employed 
in the present study was comparable to the intravenous dose of the drug used by previous 
workers in rabbits (DESTACHE et al., 2001) and man (LANGTRY and LAMB, 1998) to study 
the pharmacokinetics of levofl oxacin.
Blood and urine sampling. To conduct the disposition study, the animals were kept in 
metabolic stalls of standard size, designed in such a way that the entire quantity of urine 
excreted naturally by the animals within a certain period was automatically collected, 
without contamination or spillage, in containers placed beneath the stalls. Blood samples 
(5 mL) were withdrawn from the contralateral jugular vein into heparinized glass 
centrifuge tubes before and at 1, 2.5, 5, 7.5, 10, 15, 20, 30 min and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 
10, 12, 16 and 24 h after administration of drug. Plasma was separated by centrifugation 
at 1300 g for 15 min at room temperature and kept at -20 0C until analysis, which was 
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usually on the day after collection. Urine samples were also collected simultaneously 
from the same animals at various predetermined time intervals of 2, 4, 6, 8, 10, 12, 16 and 
24 h after administration of the drug. At the end of the given time interval, the volume of 
total urine voided and collected in the container, was measured for each animal and after 
fi ltration, 10 mL samples were taken for analysis. 
Analytical procedure. The concentration of levofl oxacin in plasma and urine samples 
was estimated by microbiological assay, using Escherichia coli (ATCC 10536) as the test 
organism. The test organism was cultured on antibiotic medium no. 1 at 37 0C for 24 h and 
a suspension was prepared in sterile normal saline. 20 mL of molten seed layer containing 
bacterial suspension was poured onto a Petri dish, with the help of a Cornwell Continuous 
Pipetting Device (Becton Dickinson, New Jersey, USA). Preliminary experiments were 
conducted to determine the actual amount of bacterial suspension to be used in the 
preparation of the seed layer. After solidifi cation of the media, six wells were punched 
at equal distances with the help of a punching device. The samples were thawed at room 
temperature and suitably diluted with phosphate buffer. The alternate three wells were 
fi lled with one plasma or urine sample and the remaining three wells with a standard 
reference solution of levofl oxacin (0.2 g/mL). These assay plates were incubated at 
34 0C for 7 h. At the end of incubation, the diameter of the zone of inhibition of each well 
was measured with a Fisher Lilly Antibiotic Zone Reader (Fisher Scientifi c Company, 
New Jersey, USA). For each sample, 9 replicates were analysed and correlated with the 
zone of inhibition of standard reference solution. The concentration of levofl oxacin in the 
samples was calculated as g/mL of plasma or urine. This method estimated the level of 
parent drug and its active metabolites having antibacterial activity. The assay could detect 
a minimum of 0.1 g/mL of levofl oxacin.
Calculation of disposition parameters. Various disposition parameters were calculated 
manually by the least-squares regression technique (GIBALDI and PERRIER, 1982). The 
mean pharmacokinetic variables were obtained by averaging the variables calculated for 
drug disposition after intravenous drug administration to each animal. 
Results 
After a single intravenous injection of E. coli endotoxin (1 g.kg-1), fever was 
induced within 60-90 min and persisted up to 12 h. During the experimental period, the 
body temperature of febrile animals ranged between 39.0 ± 0.11 ºC to 39.8 ± 0.05 ºC. 
The mean plasma concentrations of levofl oxacin in febrile calves, as a function of time 
on a semilogarithmic scale, are presented in Fig. 1. At 1 min, the mean plasma drug 
concentration was 15.8 ± 0.55 g/mL which rapidly declined to 5.61 ± 0.18 g/mL at 10 
min and then declined gradually to 0.16 ± 0.01 g/mL at 12 h. Evaluation of the results 
revealed that the disposition pattern of levofl oxacin was best fi tted into a 2-compartment 
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open model, and it was adequately described by the bi-exponential equation: Cp = Ae-
t + 
Be-t, where, Cp is the plasma level of levofl oxacin at time t and e represents the base of 
natural logarithm. A, and B are the extrapolated zero-time intercepts of the distribution 
and elimination phases, respectively.  and β are the distribution and elimination rate 
constants, respectively. 
Fig. 1. Semilogarithmic plot of plasma concentration-time profi le of levofl oxacin following 
its single intravenous injection of 4 mg/kg body mass in febrile cross bred calves. Values are 
presented as mean ± SE of 6 animals. The data were analyzed according to the two-compartment 
open model. Distribution () and elimination () phases are represented by least square regression 
lines. The calculated points (o) of distribution phases were obtained by the feathering technique. 
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Various disposition parameters, describing the distribution and elimination pattern 
of levofl oxacin in febrile calves, were calculated and presented in Table 1. The mean 
cumulative amount and per cent of total dose of levofl oxacin excreted in urine at different 
time intervals, are shown in Table 2. Using convenient dosage interval and the values of  
and Vdarea from Table 1, the priming (D) and maintenance (D’) doses of levofl oxacin were 
calculated from following equations: 
D = Cp(min)
  Vd (e) D' = Cp (min)  Vd (e-1) 
where, Cp (min)  is the minimum therapeutic concentration of levofl oxacin, Vd is 
the apparent volume of distribution, β is the elimination rate constant and  is the dosing 
interval (BAGGOT, 1977).
Table 1. Disposition of levofl oxacin in febrile calves (n = 6) following single intravenous dose of 
4 mg/kg body mass
Parameter Unit Mean ± SE
Cp0 mg/mL 14.6 ± 0.69
A mg/mL 11.3 ± 0.44
B mg/mL 3.26 ± 0.39
 h-1 9.93 ± 0.73
 h-1 0.314 ± 0.009
t1/2 h 0.07 ± 0.01
t1/2 h 2.22 ± 0.07
K12 h
-1 6.43 ± 0.49
K21 h
-1 2.51 ± 0.32
AUC mg/mL/h 11.5 ± 0.95
Vdarea L/kg 1.18 ± 0.15
ClB L/kg/h 0.36 ± 0.03
Kel h
-1 1.30 ± 0.08
MRT h 2.85 ± 0.03
td h 11.8 ± 0.37
P/C ratio 3.20 ± 0.41
Vc L/kg 0.28 ± 0.01
AUC/MIC ratio 114.5 ± 9.49
Cp0 = plasma drug concentration at time zero after intravenous dose;  and A = distribution rate constant from 
central to peripheral compartment and the zero time intercept of distribution phase, respectively; B and  = 
zero time intercept of the elimination phase and elimination rate constant, respectively; t1/2 = distribution half 
life; t1/2 = elimination half life; K12 and K21 are rate constants of drug transfer from central to peripheral and 
from peripheral to central compartment, respectively; Kel = rate constant for elimination of drug from central 
compartment; AUC = area under the plasma-concentration time curve; Vdarea = apparent volume of distribution; 
ClB = total body clearance of drug; MRT = mean residence time; td = total duration of pharmacological effect; 
P/C = ratio of drug present in peripheral to central compartment; Vc = volume of central compartment; MIC = 
minimum inhibitory concentration of levofl oxacin. 
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cent of total dose 
excreted
0-2 40.8 ± 7.65 12.2 ± 1.69 0-2 40.8 ± 7.65 12.2 ± 1.69 
2-4 51.4 ± 15.1 14.5 ± 3.19 0-4 70.0 ± 13.4 20.2 ± 2.90 
4-6 25.4 ± 1.69 8.17 ± 1.54 0-6 95.4 ± 12.7 28.4 ± 3.33 
6-8 18.5 ± 2.10 5.19 ± 0.93 0-8 110.9 ± 14.7 32.7 ± 3.23 
8-10 5.60 ± 0.91 1.62 ± 0.35 0-10 115.5 ± 14.9 34.1 ± 3.23 
10-12 4.46 ± 0.39 1.37 ± 0.18 0-12 120.0 ± 14.9 35.4 ± 3.23 
12-16 4.26 ± 0.94 1.16 ± 0.26 0-16 123.5 ± 15.7 36.4 ± 3.30
16-24 4.23 ± 1.11 1.30 ± 0.33 0-24 127.8 ± 15.6 37.7 ± 3.31 
The values given at different time intervals are mean ± SE of the results obtained from 6 animals 
Discussion 
In accordance with our fi ndings, the disposition curve of levofl oxacin and other 
fl uoroquinolones, pefl oxacin and enrofl oxacin, after intravenous administration, have 
been reported to follow two-compartment open model in healthy and febrile calves 
(DUMKA et al., 2000; DUMKA and SRIVASTAVA, 2007; AHANGER and SRIVASTAVA, 
2000; SRIVASTAVA et al., 2000). An average plasma concentration of 0.008-0.125 
mg/mL has been reported to be the minimum inhibitory concentration (MIC) of 
levofl oxacin against most gram-positive, gram-negative and atypical bacteria, 
including Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus spp., 
Corynebacterium spp., Bacillus spp., Pseudomonas aeruginosa, Escherichia coli, 
Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, 
Enterococcus faecalis, and Haemophilus infl uenzae of human and animal models of 
infection (DRAGO et al., 2001; HO et al., 2004; GRIFFITH et al., 2006; DUGGIRALA et 
al., 2007). In this discussion, an average MIC90 of 0.1 mg/mL of levofl oxacin has 
been taken into consideration. At 1 min of injection, the plasma level (15.8 ± 0.55 
mg/mL) was approximately 158 fold higher than the MIC of levofl oxacin and the 
drug was detected in plasma up to 12 h of administration. Levofl oxacin was rapidly 
transferred from the central to peripheral compartment in febrile calves, as is evident 
from the high values of distribution rate constant (9.93 ± 0.73 h) and K12 (6.43 ± 
0.49 h). Comparable values of distribution rate constant (12.2 h) and K12 (7.43 h) 
were reported after a single intravenous injection of levofl oxacin in healthy calves 
(DUMKA and SRIVASTAVA, 2007). The high value of P/C ratio (3.2 ± 0.41) and apparent 
volume of distribution refl ected that levofl oxacin penetrated well into various body 
377Vet. arhiv 83 (4), 371-380, 2013
V. K. Dumka and A. K. Srivastava: Levofl oxacin disposition in febrile calves
fl uids and tissues. The value of Vdarea established in the present study (1.18 ± 0.15 
L/kg) is in agreement with the fi ndings of LANGTRY and LAMB (1998) and DUMKA 
and SRIVASTAVA (2006), who reported the volume of distribution of levofl oxacin to 
be 0.94 L/kg in man and 1.02 L/kg in calves, respectively. However, the volume of 
distribution of another fl uoroquinolone used in veterinary medicine, enrofl oxacin, 
was 0.4 L/kg after intravenous administration in calves (AHANGER et al., 2003). 
Consistent with the high AUC (11.5 ± 0.95 mg/mL/h) in the present fi nding, high 
values for AUC of levofl oxacin have been reported in man (55.3 mg/mL/h), rabbits 
(29.7 mg/mL/h) and calves (12.7 mg/mL/h) (LANGTRY and LAMB, 1998; DESTACHE 
et al., 2001; DUMKA and SRIVASTAVA, 2007). High values of AUC have also been 
reported after intravenous administration of other fl uoroquinolones used in veterinary 
medicine: marbofl oxacin (7.7 mg/mL/h) in cattle and enrofl oxacin (17.8 mg/mL/h) 
in calves (AHANGER et al., 2003; THOMAS et al., 1994). The total body clearance of 
levofl oxacin in the present study was 0.36 ± 0.03 L/kg/h. This fi nding is in agreement 
with the values of ClB reported for levofl oxacin (0.32 L/kg/h) and enrofl oxacin (0.28 
L/kg/h) in healthy calves and marbofl oxacin (0.3 L/kg/h) in cattle after intravenous 
administration (DUMKA and SRIVASTAVA, 2007; AHANGER et al., 2003; THOMAS et 
al., 1994). The elimination half-life of levofl oxacin in febrile calves calculated in this 
study (2.22 ± 0.07 h) was shorter than 5.7 h for marbofl oxacin in cattle (THOMAS et 
al., 1994) but longer than the t½ β of 1.61h for levofl oxacin and 0.95 h for enrofl oxacin 
in healthy calves (DUMKA and SRIVASTAVA, 2007; AHANGER et al., 2003) indicating 
rapid elimination of the drug during fever in calves.
The amount of levofl oxacin-equivalent inhibitory units excreted in the urine of febrile 
calves was very high (4.23 ± 1.11 mg), even 24 h after administration. Approximately 
37.7 per cent of the microbiological activity of the administered drug was recovered in 
the urine of calves within 24 h, which was greater than the 27.3 % urinary recovery of 
levofl oxacin after intravenous administration in healthy calves (DUMKA and SRIVASTAVA, 
2007). These fi ndings suggest that levofl oxacin may be an appropriate drug for treating 
urinary tract infections in cattle. 
The objective of the pharmacokinetic study was to determine an appropriate intravenous 
dosage regimen of levofl oxacin during fever in calves. On the basis of the present study, 
the loading and maintenance doses of levofl oxacin, at a dosage interval of 12 h, were 
calculated to be 4.92 and 4.8 mg/kg, respectively, or under fi eld conditions, for most 
bacteria sensitive to levofl oxacin, the most appropriate dosage regimen for levofl oxacin, 
would be 5 mg/kg at 12 h intervals for the treatment of bacterial infections manifested 
with fever in calves. This dosage was higher than the intravenous dose of 3 mg/kg at 12 
h intervals suggested for levofl oxacin in healthy calves (DUMKA and SRIVASTAVA, 2007).
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SAŽETAK
Istražena je raspodjela levofl oksacina i njegovo izlučivanje mokraćom nakon jednokratne intravenske 
primjene u dozi od 4 mg/kg tjelesne mase u šestero febrilne križane teladi. Razine lijeka u plazmi i mokraći bile 
su procijenjene na osnovi mikrobiološkog postupka. Levofl oksacin se brzo proširio iz krvi u tkiva što je vidljivo 
po  visokim vrijednostima koefi cijenta raspodjele (9,93 ± 0,73 h). Visoki AUC (površina ispod krivulje) (11,5 
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± 0,95 g/mL/sat) upućuje na dobro antibakterijsko djelovanje levofl oksacina u teladi. Poluvrijeme eliminacije 
iznosilo je 2,22 ± 0,07 sati, volumen raspodjele 1,18 ± 0,15 L/kg, a ukupni klirens 0,36 ± 0,03 L/kg/sat. Oko 
37,7% primijenjene doze levofl oksacina bilo je tijekom 24 sata izlučeno putem mokraće. Kod bakterijskih 
zaraza što se očituju vrućicom levofl oksacin treba primijeniti u dozi od 5,0 mg/kg u razmaku od 12 sati. 
Ključne riječi: telad, raspodjela, vrućica, levofl oksacin ________________________________________________________________________________________
